Despite a recent dip, major U.S. stock indexes remain near their all-time highs, reflecting a resilient market even as inflationary pressures persist. In this context, penny stocks—often representing smaller or newer companies—offer unique growth opportunities at lower price points. When these stocks are supported by robust financial health and solid fundamentals, they can present promising prospects for investors looking to uncover potential hidden gems in the market.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Dingdong (Cayman) (DDL) | $2.03 | $435.04M | ✅ 4 ⚠️ 0 View Analysis > |
| Waterdrop (WDH) | $1.94 | $701.63M | ✅ 4 ⚠️ 0 View Analysis > |
| Puma Biotechnology (PBYI) | $4.84 | $243.79M | ✅ 3 ⚠️ 2 View Analysis > |
| Sensus Healthcare (SRTS) | $3.10 | $50.96M | ✅ 4 ⚠️ 2 View Analysis > |
| Performance Shipping (PSHG) | $1.96 | $24.37M | ✅ 4 ⚠️ 2 View Analysis > |
| Golden Growers Cooperative (GGRO.U) | $5.00 | $77.45M | ✅ 2 ⚠️ 5 View Analysis > |
| Table Trac (TBTC) | $4.372 | $20.28M | ✅ 2 ⚠️ 2 View Analysis > |
| BAB (BABB) | $0.9994 | $7.26M | ✅ 2 ⚠️ 3 View Analysis > |
| Lifetime Brands (LCUT) | $3.82 | $86.55M | ✅ 3 ⚠️ 2 View Analysis > |
| Universal Safety Products (UUU) | $4.23 | $9.78M | ✅ 2 ⚠️ 3 View Analysis > |
Click here to see the full list of 369 stocks from our US Penny Stocks screener.
Let's uncover some gems from our specialized screener.
NET Power (NPWR)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: NET Power Inc. is a U.S.-based energy technology company with a market cap of approximately $664.25 million.
Operations: Currently, there are no reported revenue segments for this U.S.-based energy technology company.
Market Cap: $664.25M
NET Power Inc., with a market cap of US$664.25 million, is pre-revenue, generating less than US$1 million annually. The company reported a significant net loss of US$28.14 million for Q2 2025, up from the previous year's loss of US$4.27 million. Despite being debt-free and having short-term assets of $408.5M that exceed liabilities, its earnings have declined by 23.4% annually over five years, and it remains unprofitable with high volatility in its share price. The management team and board are relatively new, suggesting potential challenges in strategic execution moving forward.
- Navigate through the intricacies of NET Power with our comprehensive balance sheet health report here.
- Evaluate NET Power's prospects by accessing our earnings growth report.
Under Armour (UAA)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Under Armour, Inc., along with its subsidiaries, develops, markets, and distributes performance apparel, footwear, and accessories for men, women, and youth with a market cap of approximately $2.11 billion.
Operations: Under Armour generates revenue through its geographical segments, with North America contributing $3.07 billion, EMEA at $1.11 billion, Asia-Pacific at $737 million, and Latin America at $206 million.
Market Cap: $2.11B
Under Armour, Inc., with a market cap of US$2.11 billion, has recently turned profitable after several years of growth challenges. The company reported a net loss of US$2.61 million for Q1 2025, an improvement from the previous year's significant loss. Its short-term assets of US$2.9 billion exceed both its short and long-term liabilities, indicating financial stability despite negative operating cash flow. Under Armour's debt to equity ratio has improved over five years to 52.8%, and interest payments are well covered by EBIT at 17.5 times coverage, although return on equity remains low at 5.4%.
- Jump into the full analysis health report here for a deeper understanding of Under Armour.
- Gain insights into Under Armour's outlook and expected performance with our report on the company's earnings estimates.
Elite Pharmaceuticals (ELTP)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and selling oral controlled-release and generic pharmaceuticals with a market cap of $742.59 million.
Operations: Elite Pharmaceuticals generates revenue primarily from its Abbreviated New Drug Applications (ANDA) segment, totaling $105.45 million.
Market Cap: $742.59M
Elite Pharmaceuticals, Inc., with a market cap of US$742.59 million, has demonstrated substantial revenue growth, reporting US$40.21 million for Q1 2025 compared to US$18.8 million the previous year. Despite this increase, the company remains unprofitable with a net loss of US$5.88 million for the quarter and negative return on equity at -22.68%. Elite's financial stability is supported by short-term assets exceeding both short and long-term liabilities and cash surpassing total debt levels. However, significant insider selling over the past three months may raise concerns among investors regarding future prospects despite its experienced management team and board of directors.
- Take a closer look at Elite Pharmaceuticals' potential here in our financial health report.
- Examine Elite Pharmaceuticals' past performance report to understand how it has performed in prior years.
Where To Now?
- Unlock more gems! Our US Penny Stocks screener has unearthed 366 more companies for you to explore.Click here to unveil our expertly curated list of 369 US Penny Stocks.
- Looking For Alternative Opportunities? Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Elite Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com